Annual CFF
$639.81 M
-$221.73 M-25.74%
31 December 2023
Summary:
Vaxcyte annual cash flow from financing activities is currently $639.81 million, with the most recent change of -$221.73 million (-25.74%) on 31 December 2023. During the last 3 years, it has risen by +$264.94 million (+70.68%). PCVX annual CFF is now -25.74% below its all-time high of $861.55 million, reached on 31 December 2022.PCVX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$1.52 B
+$1.40 B+1272.71%
30 September 2024
Summary:
Vaxcyte quarterly cash flow from financing activities is currently $1.52 billion, with the most recent change of +$1.40 billion (+1272.71%) on 30 September 2024. Over the past year, it has increased by +$1.47 billion (+3020.57%). PCVX quarterly CFF is now at all-time high.PCVX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$2.45 B
+$1.47 B+149.66%
30 September 2024
Summary:
Vaxcyte TTM cash flow from financing activities is currently $2.45 billion, with the most recent change of +$1.47 billion (+149.66%) on 30 September 2024. Over the past year, it has increased by +$1.15 billion (+89.09%). PCVX TTM CFF is now at all-time high.PCVX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PCVX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -25.7% | +3020.6% | +89.1% |
| 3 y3 years | +70.7% | +10000.0% | +10000.0% |
| 5 y5 years | +928.8% | +10000.0% | +10000.0% |
PCVX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -25.7% | +3495.3% | at high | >+9999.0% | at high | >+9999.0% |
| 5 y | 5 years | -25.7% | +3495.3% | at high | >+9999.0% | at high | >+9999.0% |
| alltime | all time | -25.7% | +3495.3% | at high | >+9999.0% | at high | >+9999.0% |
Vaxcyte Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.52 B(+1272.7%) | $2.45 B(+149.7%) |
| June 2024 | - | $110.37 M(-86.5%) | $979.85 M(-30.8%) |
| Mar 2024 | - | $818.20 M(>+9900.0%) | $1.42 B(+121.4%) |
| Dec 2023 | $639.81 M(-25.7%) | $2.73 M(-94.4%) | $639.81 M(-50.5%) |
| Sept 2023 | - | $48.55 M(-91.1%) | $1.29 B(+0.4%) |
| June 2023 | - | $546.97 M(+1216.0%) | $1.29 B(+62.8%) |
| Mar 2023 | - | $41.56 M(-93.7%) | $792.09 M(-8.1%) |
| Dec 2022 | $861.55 M(+4741.2%) | $656.63 M(+1391.8%) | $861.55 M(+303.2%) |
| Sept 2022 | - | $44.02 M(-11.8%) | $213.67 M(+20.5%) |
| June 2022 | - | $49.88 M(-55.1%) | $177.25 M(+38.1%) |
| Mar 2022 | - | $111.02 M(+1168.2%) | $128.33 M(+621.1%) |
| Dec 2021 | $17.80 M | $8.75 M(+15.2%) | $17.80 M(+85.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $7.60 M(+694.9%) | $9.60 M(+371.8%) |
| June 2021 | - | $956.00 K(+96.3%) | $2.03 M(-99.2%) |
| Mar 2021 | - | $487.00 K(-12.3%) | $265.56 M(-29.2%) |
| Dec 2020 | $374.87 M(+801.8%) | $555.00 K(+1441.7%) | $374.87 M(-9.8%) |
| Sept 2020 | - | $36.00 K(-100.0%) | $415.67 M(-0.1%) |
| June 2020 | - | $264.48 M(+140.9%) | $416.00 M(+174.7%) |
| Mar 2020 | - | $109.80 M(+165.5%) | $151.44 M(+264.3%) |
| Dec 2019 | $41.57 M(-33.2%) | $41.35 M(>+9900.0%) | $41.57 M(>+9900.0%) |
| Sept 2019 | - | $368.00 K(-577.9%) | $215.00 K(-240.5%) |
| June 2019 | - | -$77.00 K(+1.3%) | -$153.00 K(+101.3%) |
| Mar 2019 | - | -$76.00 K | -$76.00 K |
| Dec 2018 | $62.19 M | - | - |
FAQ
- What is Vaxcyte annual cash flow from financing activities?
- What is the all time high annual CFF for Vaxcyte?
- What is Vaxcyte annual CFF year-on-year change?
- What is Vaxcyte quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Vaxcyte?
- What is Vaxcyte quarterly CFF year-on-year change?
- What is Vaxcyte TTM cash flow from financing activities?
- What is the all time high TTM CFF for Vaxcyte?
- What is Vaxcyte TTM CFF year-on-year change?
What is Vaxcyte annual cash flow from financing activities?
The current annual CFF of PCVX is $639.81 M
What is the all time high annual CFF for Vaxcyte?
Vaxcyte all-time high annual cash flow from financing activities is $861.55 M
What is Vaxcyte annual CFF year-on-year change?
Over the past year, PCVX annual cash flow from financing activities has changed by -$221.73 M (-25.74%)
What is Vaxcyte quarterly cash flow from financing activities?
The current quarterly CFF of PCVX is $1.52 B
What is the all time high quarterly CFF for Vaxcyte?
Vaxcyte all-time high quarterly cash flow from financing activities is $1.52 B
What is Vaxcyte quarterly CFF year-on-year change?
Over the past year, PCVX quarterly cash flow from financing activities has changed by +$1.47 B (+3020.57%)
What is Vaxcyte TTM cash flow from financing activities?
The current TTM CFF of PCVX is $2.45 B
What is the all time high TTM CFF for Vaxcyte?
Vaxcyte all-time high TTM cash flow from financing activities is $2.45 B
What is Vaxcyte TTM CFF year-on-year change?
Over the past year, PCVX TTM cash flow from financing activities has changed by +$1.15 B (+89.09%)